The marked NMO pathology seen in CD59−/− rats following AQP4-IgG administration contrasts with the conclusions of Saadoun and Papadopoulos [27], who concluded that complement inhibitors, including CD59, are not protective against complement injury in CNS tissues. The gene discussed is CD59; the disease is neuromyelitis optica.